아덱스 테라퓨틱스(ADXN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.40 (+1.19%), 시가총액 $0.01B, 52주 최저~최고 $5.66 ~ $10.95.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Jan
아덱스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아덱스 테라퓨틱스의 현재 주가는 $3.40 (+1.19%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아덱스 테라퓨틱스의 시가총액은 약 $0.01B입니다.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupl